Obermatt
See Similar Stocks →

Evotec

GER:EVT · DE0005664809
Life Sciences Tools & ServicesMedium

360

17
Profit price56
Owner Earnings Yield1
Dividend Yield1
Price/Sales93
EV / Gross Profit41
Price/Book76
Return on Capital42
Cash Return on Capital23
Return on Equity28
EBIT Margin37
Gross Profitability10
Accruals87
Owner Earnings Margin34
Sales growth8
Profit growth5
Reinvestment51
Price momentum16
Debt load39
Refinancing6
Debt Payback1
Liquidity4
Analyst ratings43
Opinion Changes92
Price Target Upside68
Market mood3
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Evotec doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryGermany
IndustryLife Sciences Tools & Services
SizeMedium
TypePublic Company
ExchangeXTRA
Founded1993
Employees2,802
Websiteevotec.com
ISINDE0005664809
Last UpdateApr 2, 2026
Indices
CDAX (Germany)SDAX (Germany)NASDAQ (USA)TecDAX (Germany)
Themes
Health DiagnosticsImmunologyCardiovascularOncologyDiabetesStem Cell TherapyInflammationWomen's HealthCentral Nervous SystemBiopharmaBiotechnologyNeurosciencePharmaceutical

Description

Evotec SE (Evotec), operates as a drug discovery and development organization. The company envisions drug discovery, preclinical development, and manufacturing as a seamless continuum. The company's ambition is to lead the industry by combining comp…

Analysis

Middle-of-the-road

Evotec SE is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 4/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
13
2023202420252026

All-time high

67

Oct 2025

All-time low

6

Jan 2025

Average rank

30

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
93
80
40
14
Price/Earnings
80
1
6
1
Price/Book
76
82
41
45
Dividend Yield
1
1
1
1
Value (overall)
82
80
15
15

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Evotec with its peers
Immunocore
NSQ:IMCR
40
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Compugen
NAQ:CGEN
19
CountryIsrael
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sandoz
SWX:SDZ
18
CountrySwitzerland
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Roche
VTX:ROG
84
CountrySwitzerland
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Recordati
MIL:REC
54
CountryItaly
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Sanofi India
NSI:SANOFI
56
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →